Assessing when to initiate anticoagulation in atrial fibrillation is not improved by including gender, says the ESC in their ...

In this retrospective cohort of patients with atrial fibrillation (AF) who underwent transcatheter aortic valve replacement ...

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, today highlighted a key opinion leader presen ...

Request To Download Free Sample of This Strategic Report @- The Global Geriatric Medicines Market is on the brink of unprecedented growth, projected to reach over USD 1,157.34 billion by 2026, ...

Uttarakhand government endorses medicinal leech therapy as a non-invasive treatment for post-surgical recovery and skin rejuvenation, amidst growing interest and some controversy.

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to provide safer and ...